All posts by CAC2

Assorted news from last week: The FDA has granted a rare pediatric disease designation (RPDD) to lutetium-177(177Lu)-omburtamab-DTPA for use as a potential therapeutic option in pediatric patients with medulloblastoma, according to an announcement from CAC2 Member Y-mAbs Therapeutics, Inc.,  developer of the product. Cancers in children, adolescents and young adults can be resistant to medical treatments or recur even when initial treatments appear successful.  Findings of a 10-year study led by the Translational Genomics Research Institute (TGen), an affiliate of City of Hope, and in collaboration with the Beat Childhood Cancer Research Consortium, suggest that deeper genomic analysis and therapies […]

Read more

Assorted news from last week: CAC2 Member Mary Beth Collins, highlights the importance of Childhood Cancer License Plates, how they amplify awareness efforts, the advocacy required to create these plates and CAC2’s Childhood Cancer License Plate awareness effort. Gavin Lindberg had an Opinion Piece published in The Washington Post titled “The US Should Invest in Children’s Health.” From the New England Journal of Medicine correspondence: Lorlatinib in a Child with ALK-Fusion–Positive High-Grade Glioma Mount Sinai researchers have developed a therapy that shows promise against acute myeloid leukemia. A new study based on patient samples collected over the past decade by [...] Read more

Assorted news from the last two weeks: In recognition of Childhood Cancer Awareness Month, NCI Director Ned Sharpless reflected on the progress that’s been made against cancers that largely affect children. New Jersey established the “Pediatric Cancer Research Fund” and an advisory board within the New Jersey State Commission on Cancer Research for disbursement of monies deposited in the fund and provides voluntary contributions by taxpayers on gross income tax returns for pediatric cancer research. Additionally, S3724 appropriates $5 million to the New Jersey Pediatric Cancer Fund. A study of children with cancer identified an association between physical activity, fatigue, […]

Read more

Assorted news from the last week: This video abstract breaks down financial toxicity issues for families with special health care needs. Researchers have discovered that low-risk and high-risk neuroblastoma have different cell identities, which can affect the survival rate. Cisplatin, a chemotherapy drug known to cause hearing loss in children is more likely to do so the earlier in life children receive it, new UBC research has found. A new study of palliative care in pediatric oncology has found that non-White children were more likely to die in the hospital than White patients, but that the difference was in concordance with […]

Read more

Assorted news from the last week: The White House issued a proclamation for Childhood Cancer Awareness Month on September 1. Canadian gold illumination! For every post that uses #KickChildhoodCancer on Twitter, Continental Tire will donate $1 to Children Oncology Group (up to $50,000) from September 1 – 30, 2021. Amazon Goes Gold helps fund pediatric cancer research, and is marking the campaign’s fifth year by highlighting important research over the last five years. Systematic ongoing follow-up of pediatric cancer patients who survive their disease is important to provide for early detection of and intervention for potentially serious late-onset complications. In […]

Read more

Assorted news from the last week: Research led by SickKids and the Montreal Children’s Hospital of the McGill University Health Centre found that a novel cancer predisposition screening tool shows promise for helping doctors better predict which childhood cancer survivors may be at risk of developing future cancers. A Lancet study examined a global cohort of children and adolescents with cancer and COVID-19. Children and adolescents with cancer and SARS-CoV-2 infection were more likely to develop severe and critical cases of COVID-19 compared with the general pediatric population. A new study has shown that the tumor-inhibiting gene TET2 is silenced […]

Read more

Assorted news from the last week: Study finds cancer screening tool may help predict risk of developing new cancer among childhood cancer survivors. NCI has formed a new task force that aims to address gaps in information about quality of life experienced by AYA cancer survivors.  This task force will gather information directly from AYAs on how cancer and cancer treatments affect their quality of life—information known as patient-reported outcomes. A key goal of the task force is developing ways to standardize the collection of patient-reported outcomes from AYAs participating in clinical trials conducted through the NCI Community Oncology Research […]

Read more

Assorted news from the last week: The STAR Act was crafted by parents, doctors, and organizations who strive to make a difference for children with cancer and their families, in partnership with legislators and others.  CAC2 Member Danielle Leach explains its importance in this CDC blog post. Adding temozolomide to a combination of vincristine and irinotecan (VIT) improved tumor response and survival in patients with relapsed or refractory rhabdomyosarcoma in a European phase II trial. In some children with acute myeloid leukemia, cancer cells have the same amount of DNA changes as healthy blood stem cells. Researchers were surprised to […]

Read more